Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting early-phase tilt top decile by trial count

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair: 10 sponsored US clinical trials, none currently recruiting.

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is SCLC, with 1 trials.

Top-decile sponsor footprint

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

10 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 2

Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms

NCT05987956
ACTIVE NOT RECRUITING Early Phase 1

Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix

NCT07182838
ACTIVE NOT RECRUITING Phase 2

Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms

NCT07145333
ACTIVE NOT RECRUITING Phase 2

Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms

NCT01064466
ACTIVE NOT RECRUITING Phase 2

Pharmacogenomics ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms

NCT06062810
ACTIVE NOT RECRUITING Phase 2

Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers

NCT07033585
ACTIVE NOT RECRUITING Early Phase 1

Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix

NCT03305341
ACTIVE NOT RECRUITING Early Phase 1

Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV

NCT06959563
ACTIVE NOT RECRUITING Phase 2

Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms

NCT03348670
ACTIVE NOT RECRUITING Phase 1

Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer

NCT02403505

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 6

Therapeutic Areas

SCLC 1
HPV Infection 1
Type 2 Diabetes 1
HIV Infections 1
Rectal Cancer 1
Breast Cancer 1
COVID-19 1
Small-cell Lung Cancer 1
Prostate Cancer 1

How the Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair early-phase archive is shaped

10 indexed studies, none listed as recruiting (0% open).

Phase mix: 0 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: SCLC (1 trial), 8 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair page

10 registered trials is a research-attention snapshot, not an endorsement of Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair or any single study.

  • None of Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • SCLC is the condition Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair studies most, compare against other sponsors active in the same condition before evaluating a specific study. See SCLC trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair pipeline card: 10 registered trials from official public datasets.Report a data error.